Literature DB >> 33540604

Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.

Vassilios P Memtsas1, Deepa R J Arachchillage2,3,4, Diana A Gorog1,5,6.   

Abstract

Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in various disease states and assessment of cardiovascular risk.

Entities:  

Keywords:  coagulation; endogenous fibrinolysis; factor XIII; fibrin; thrombosis

Mesh:

Substances:

Year:  2021        PMID: 33540604      PMCID: PMC7867291          DOI: 10.3390/ijms22031472

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  166 in total

Review 1.  Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis.

Authors:  Arjun Deb; Noel M Caplice
Journal:  Clin Cardiol       Date:  2004-05       Impact factor: 2.882

2.  Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.

Authors:  K Kokame; X Zheng; J E Sadler
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

3.  Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin.

Authors:  T Takagi; R F Doolittle
Journal:  Biochemistry       Date:  1974-02-12       Impact factor: 3.162

4.  Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2).

Authors:  H Ritchie; L C Lawrie; M W Mosesson; N A Booth
Journal:  Ann N Y Acad Sci       Date:  2001       Impact factor: 5.691

Review 5.  Factor XIII and venous thromboembolism.

Authors:  Zsuzsanna Bereczky; László Muszbek
Journal:  Semin Thromb Hemost       Date:  2011-03-31       Impact factor: 4.180

6.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

7.  B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'.

Authors:  N Okumura; F Terasawa; A Haneishi; N Fujihara; M Hirota-Kawadobora; K Yamauchi; H Ota; S T Lord
Journal:  J Thromb Haemost       Date:  2007-10-08       Impact factor: 5.824

8.  Fibrin clot structure in patients with end-stage renal disease.

Authors:  Jonas A Sjøland; Johannes J Sidelmann; Mikkel Brabrand; Robert S Pedersen; Jørgen H Pedersen; Kim Esbensen; Kristina F Standeven; Robert A S Ariëns; Jørgen Gram
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

9.  Ca2+-related regulatory function of fibrinogen.

Authors:  R B Credo; C G Curtis; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 10.  Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.

Authors:  Anetta Undas; Robert A S Ariëns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-11       Impact factor: 8.311

View more
  1 in total

Review 1.  Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.

Authors:  José Miguel Rivera-Caravaca; Anny Camelo-Castillo; Inmaculada Ramírez-Macías; Pablo Gil-Pérez; Cecilia López-García; María Asunción Esteve-Pastor; Esteban Orenes-Piñero; Antonio Tello-Montoliu; Francisco Marín
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.